Influence of Biomarkers on Mortality among Patients with Hepatic Metastasis of Colorectal Cancer Treated with FOLFOX/CAPOX and FOLFIRI/CAPIRI, Including Anti-EGFR and Anti-VEGF Therapies

Dorel Popovici ¹, Cristian Stanisav ², Laurentiu V Sima ³

⁰Department of Oncology, Faculty of Medicine, Victor Babeş University of Medicine and Pharmacy Timisoara, Eftimie Murgu Square 2, 300041 Timisoara, Romania.

Medicina (Kaunas, Lithuania) +

|

June 27, 2024

View abstract on PubMed

Summary

Prognostic factors for metastatic colorectal cancer (CRC) survival were identified. Higher BMI and lymphocyte counts improved outcomes, while inflammation indices like the Neutrophil-Lymphocyte Ratio (NLR) predicted poorer survival in CRC patients.

Area Of Science

Oncology
Clinical Research
Biomarker Discovery

Background

Colorectal cancer (CRC) poses a significant global health burden, particularly in its metastatic stages.
Metastatic CRC (mCRC) is associated with increased morbidity and mortality.
Identifying prognostic factors is crucial for improving patient outcomes in mCRC.

Purpose Of The Study

To investigate the prognostic significance of clinical and laboratory parameters in patients with metastatic CRC.
To evaluate the association between various biomarkers and survival outcomes in mCRC.
To determine the impact of hepatic metastasis on overall survival in CRC patients.

Main Methods

Retrospective analysis of 188 metastatic CRC patients.
Examination of demographic, clinical, and biomarker data, including lymphocyte counts and inflammation indices.
Statistical analysis using logistic regression, Kaplan-Meier survival analysis, and ROC curves.

Main Results

Higher Body Mass Index (BMI) and lymphocyte counts correlated with better survival.
Elevated Neutrophil-Hemoglobin-Lymphocyte (NHL) score, Neutrophil-Lymphocyte Ratio (NLR), Platelet-Lymphocyte Ratio (PLR), and Systemic Immune-Inflammation Index (SII) predicted poorer outcomes.
Hepatic metastasis at diagnosis significantly reduced overall survival in CRC patients.

Conclusions

Prognostic evaluation in CRC should adopt a multi-dimensional approach, integrating traditional metrics with a broader spectrum of biomarkers.
Biomarkers like BMI, lymphocyte count, NLR, PLR, and SII offer valuable prognostic information for metastatic CRC.
Further validation and integration of these biomarkers into clinical practice can enhance prognostic accuracy and personalize treatment strategies for CRC.

Keywords:

Body Mass Index (BMI) NHL score NLR PLR ROC curve SII biomarkers colorectal cancer lymphocytes patient demographics survival analysis

Related Concept Videos

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...